ପାଫୋଲାସିଆନାଇନ

ପାଫୋଲାସିଆନାଇନ
Clinical data
Trade names	Cytalux
Synonyms	Pafolacianine sodium, OTL38, OTL-0038
data	US DailyMed: Pafolacianine;
Pregnancy; category	Not recommended;
Routes of; administration	Intravenous
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name 2-{(E)-2-[(3E)-2-(4-{2-[(4-{[(2-Amino-4-oxo-3,4-dihydro-6-pteridinyl)methyl]aminobenzoyl)amino]-2-carboxyethyl}}phenoxy)-3-{(2E)-2-[3,3-dimethyl-5-sulfo-1-(4-sulfobutyl)-1,3-dihydro-2H-indol-2-ylidene]ethylidene}-1-cyclohexen-1-yl]vinyl}-3,3-dimethyl-1-(4-sulfobutyl)-3H-indolium-5-sulfonate;
Chemical and physical data
Formula	C61H67N9O17S4
Molar mass	୧,୩୨୬.୪୯ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(C2=C(C=CC(=C2)S(=O)(=O)[O-])[N+](=C1C=CC3=C(C(=CC=C4C(C5=C(N4CCCCS(=O)(=O)O)C=CC(=C5)S(=O)(=O)O)(C)C)CCC3)OC6=CC=C(C=C6)CC(C(=O)O)NC(=O)C7=CC=C(C=C7)NCC8=CN=C9C(=N8)C(=O)NC(=N9)N)CCCCS(=O)(=O)O)C;
	InChI InChI=1S/C61H67N9O17S4/c1-60(2)46-33-44(90(81,82)83)22-24-49(46)69(28-5-7-30-88(75,76)77)51(60)26-16-38-10-9-11-39(17-27-52-61(3,4)47-34-45(91(84,85)86)23-25-50(47)70(52)29-6-8-31-89(78,79)80)54(38)87-43-20-12-37(13-21-43)32-48(58(73)74)66-56(71)40-14-18-41(19-15-40)63-35-42-36-64-55-53(65-42)57(72)68-59(62)67-55/h12-27,33-34,36,48H,5-11,28-32,35H2,1-4H3,(H9-,62,63,64,66,67,68,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86)/t48-/m0/s1; Key:PDXNSXLPXJFETD-DYVQZXGMSA-N;

ପାଫୋଲାସିଆନାଇନ (ଇଂରାଜୀ ଭାଷାରେ Pafolacianine), ସାଇଟୋଲକ୍ସ ଏହାର ବେପାର ନାମ, ହେଉଛି ଫ୍ଲୋରିସେନ୍ସ-ନିୟନ୍ତ୍ରିତ ଅସ୍ତ୍ରୋପଚାରରେ ବ୍ୟବହୃତ ଏକ ପ୍ରତିକୃତି କାରକ ।^[୧] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ଓଭାରି କର୍କଟର ସ୍ଥାନ ଖୋଜିବା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ଏହା ଏକ ଶିରାରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଇ, ବାନ୍ତି, ପେଟ ଯନ୍ତ୍ରଣା, ମୁଖ ଲାଲିମା, ଛାତି ଅସ୍ୱାଭାବିକତା, ଗଲୁ ଏବଂ ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ହୋଇପାରେ ^[୧] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ । ଏହା ଏକ ଫ୍ଲୋରିସେଣ୍ଟ ଔଷଧ ଯାହା ଫୋଲେଟ୍ ରିସେପ୍ଟର ସହିତ ବନ୍ଧନ ଯୁକ୍ତ ହୋଇଥାଏ, ଯାହା ଓଭାରି କର୍କଟରେ ଅଧିକ ପରିମାଣରେ ହୋଇଥାଏ ।

୨୦୨୧ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ପାଇଁ ପାଫୋଲାସିଆନାଇନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ଅନ୍ୟାନ୍ୟ ସମାନ ଧରଣର ବ୍ୟବହୃତ ଏଜେଣ୍ଟ ମଧ୍ୟରେ ମିଥିଲିନ ବ୍ଲୁ, ଫ୍ଲୋରେସିନ ସୋଡିୟମ୍ ଏବଂ ୫-ଏଏଲଏ (5-ALA) ଅନ୍ତର୍ଭୁକ୍ତ ।^[୩]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ "Cytalux- pafolacianine injection injection". DailyMed. Archived from the original on 19 December 2021. Retrieved 18 December 2021.
↑ "FDA Approves New Imaging Drug to Help Identify Ovarian Cancer Lesions". U.S. Food and Drug Administration (FDA) (Press release). 29 November 2021. Archived from the original on 30 November 2021. Retrieved 30 November 2021. This article incorporates text from this source, which is in the public domain.
↑ Lauwerends, LJ; Abbasi, H; Bakker Schut, TC; Van Driel, PBAA; Hardillo, JAU; Santos, IP; Barroso, EM; Koljenović, S; Vahrmeijer, AL (June 2022). "The complementary value of intraoperative fluorescence imaging and Raman spectroscopy for cancer surgery: combining the incompatibles". European journal of nuclear medicine and molecular imaging. 49 (7): 2364–2376. doi:10.1007/s00259-022-05705-z. PMID 35102436.

[PI2022-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ "Cytalux- pafolacianine injection injection". DailyMed. Archived from the original on 19 December 2021. Retrieved 18 December 2021.

[FDA_PR_20211129-2] "FDA Approves New Imaging Drug to Help Identify Ovarian Cancer Lesions". U.S. Food and Drug Administration (FDA) (Press release). 29 November 2021. Archived from the original on 30 November 2021. Retrieved 30 November 2021. This article incorporates text from this source, which is in the public domain.

[3] Lauwerends, LJ; Abbasi, H; Bakker Schut, TC; Van Driel, PBAA; Hardillo, JAU; Santos, IP; Barroso, EM; Koljenović, S; Vahrmeijer, AL (June 2022). "The complementary value of intraoperative fluorescence imaging and Raman spectroscopy for cancer surgery: combining the incompatibles". European journal of nuclear medicine and molecular imaging. 49 (7): 2364–2376. doi:10.1007/s00259-022-05705-z. PMID 35102436.

[୧]

[୨]

[୩]